VGNX -- Variagenics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VGNX -- Variagenics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (72)	10/19/2001 9:29:46 PM
From: Miljenko Zuanic	Read Replies (1) of 269

OT <<BTW, I've been having fun in the EGFr stuff. (Though they are hiding the ball, the abgx Mab update at the meeting might be interesting. 4 of 4 had skin rash.)>> There is no therapy based on EGF (small molecules or antibodies) without ski rash as side effects. It indicate that drug is fairly distributed and it reach all part of the body. Interesting is PFE approach (CI-1033, from WL) where drug potency isn't prime objective. Hitting almost all erbB family receptors, with longer exposure. However, I do not like irreversible. BTW, thanks for AACR-abstracts pointer. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next